Trials / Sponsors / Aptose Biosciences Inc.

Aptose Biosciences Inc.

Industry · 8 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Terminated	A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS Acute Myeloid Leukemia, Myelodysplastic Syndromes	Phase 1	2020-10-06
Terminated	A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma	Phase 1	2019-04-30
Recruiting	Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43 Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML	Phase 1 / Phase 2	2019-03-11
Terminated	A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult, Acute Myelogenous Leukemia, Adult	Phase 1	2014-10-01
Completed	A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours Advanced or Metastatic Solid Tumours	Phase 1	2011-01-01
Completed	Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML Acute Myeloid Leukemia	Phase 2	2007-08-01
Completed	A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Pancreatic Cancer	Phase 3	2002-07-01
Completed	Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma Carcinoma, Renal Cell, Metastases, Neoplasm	Phase 1 / Phase 2	2002-03-01